Linda Spencer
Nurse Practitioner · Troy, MINPI 1134156599
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $139,751 of the $216,805 with a category attached, or 64.5%. Sanofi accounts for 94.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $96,341 and has fallen 57.1% since, to $41,348 in 2025. Among nurse practitioner clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 349 payments — averaging $621.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$206K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Amicus Therapeutics, Inc.$941
- Biomarin Pharmaceutical Inc.$511
- Amgen$483
- PTC Therapeutics, Inc.$123
- plus $123 from 3 others
What the payments were for
- Consulting fees$13,5356%
- Speaking & faculty fees$139,75164%
- Travel & lodging$54,79725%
- Food & beverage$8,7024%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 308 | $205,641 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $8,984 |
| Amicus Therapeutics, Inc. | 1 | $941 |
| Biomarin Pharmaceutical Inc. | 6 | $511 |
| Amgen(2 entities) | 4 | $483 |
| PTC Therapeutics, Inc. | 1 | $123 |
| AstraZeneca | 1 | $76 |
| Pfizer | 2 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$216,805 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CerdelgaEliglustat Tartrate | 12 | $374,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiCerdelga | $205,641 | $374,86912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Troy
- Davida KrugerDetroit$739K
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
- Lisa Astalos ChismWoodhaven$103K
- Martha GoetzPetoskey$101K
- Debra DegraffGrand Rapids$80K
- Claudia Rivera-SalasEast Lansing$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.